Antimicrobial Agents and Chemotherapy · 2008 · 71 citations · 48 references
PharmacyMedicinal ChemistryMicrobiologyAntimicrobial ResistanceDrug DesignDrug DiscoveryAntibacterial PharmacologyAntibiotic ResistanceBacterial InfectionsDrug-resistant PathogensEnterococciLinezolid ResistanceMultidrug-resistant OrganismsMultidrug-resistant PathogensNovel Antibacterial AgentsNovel Antibacterial Drug DiscoveryOxazolidinone Antibiotics
Rx-01_423 and Rx-01_667 are two members of the family of oxazolidinones that were designed using a combination of computational and medicinal chemistry and conventional biological techniques. The compounds have a two- to eightfold-improved potency over linezolid against serious gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci. This enhanced potency extends to the coverage of linezolid-resistant gram-positive microbes, especially multidrug-resistant enterococci and pneumococci. Compounds from this series expand the spectrum compared with linezolid to include fastidious gram-negative organisms like Haemophilus influenzae and Moraxella catarrhalis. Like linezolid, the Rx-01 compounds are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae.
48
Hilmar Wisplinghoff, Thomas Bischoff, Sandra Tallent et al. · Clinical Infectious Diseases · 2004 · 4.5K citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +16
Yves Gillet, B. Issartel, Philippe Vanhems et al. · The Lancet · 2002 · 1.5K citations
Katherine S. Long, Jacob Poehlsgaard, Corinna Kehrenberg et al. · Antimicrobial Agents and Chemotherapy · 2006 · 709 citations · Full text